BioPharma & Healthcare Summit on June 2 in US

The annual summit is a must attend gathering for global BioPharma industry leaders, academicians and investors. It is an invaluable forum to discuss emergent science and brainstorm new opportunities.

The USA-India Chamber of Commerce (USAIC) will organize its 10th annual BioPharma & Healthcare Summit on June 2 at the Marriott Cambridge, Massachusetts, USA. USAIC’s BioPharma & Healthcare Summit 2016 will bring together key stakeholders from the industry, academia, investors, foundations and government to engage in active debate and idea generation on ways for successful collaboration between global BioPharma companies, academia and India’s BioPharma industry and academia.

Dr Andrew Plump, Chief Medical & Scientific Officer and Board Member, Takeda Pharmaceuticals, will be the Master of Ceremonies (Emcee).

The summit will focus on BioPharma R&D strategy & trends; role of genet- ics in the therapeutic areas of Cardiovascular & Metabolic Diseases; Oncology; Neurodegenerative diseases; along with discussions on Industry-Academic Partnerships, India Clinical Research update, Global Partnerships and Funding Innovation. Role of CRISPR, AGCTs and Immune Checkpoint Inhibitor Therapy will be discussed by the most renowned people in BioPharma.

The annual summit is a must attend gathering for global BioPharma industry leaders, academicians and investors. This will be the 10th annual summit. We have been talking about ‘Ecosystem’, ‘Innovation’ and ‘Start-ups’ for the last ten years at our annual summit. It is heartening to see Prime Minister Narendra Modi actively trying to make this a reality in India. This will have a huge economic impact creating high paying jobs, intellectual property and the real possibility of India able to play a leading role in innovative drug discovery and development. Indian and global patients will be the real beneficiaries of these pragmatic policies. Connecting India’s evolving innovation ecosystem with global networks will be key to its success said Karun Rishi, President of the USA India Chamber of Commerce.

“Today’s biopharmaceutical industry is less an ‘industry’ and much more
an ‘ecosystem,’ in which partnerships between industry, academia, finance and policy makers are essential for success,” said Andy Plump, MD, PhD, Chief Medical and Scientific Officer and Director, Takeda Pharmaceuticals, and Master of Ceremonies of the summit. “In this environment, forums like the 10th US-India BioPharma & Healthcare Summit are an invaluable forum to discuss emergent science and brainstorm new opportunities.”

“Human genetics plays a significant role in the pathophysiology of many rare and devastating diseases,” said Martin Mackay, PhD, Global Head of R&D at Alexion and USAIC Advisory Board member.

“Those of us working to develop transformative medicines for patients suffering with these diseases understand that global collaboration among scientists, the pharmaceutical industry and government agencies is increasingly necessary to bring forward new treatments. As a member of the Board of the 10th Annual BioPharma and Healthcare Summit, I look forward to bringing together a multi-disciplinary group from across the globe to foster collaboration, partnership and innovation with the ultimate aim of developing new therapies and providing hope to patients”.

“Access and affordability are the two pivotal points around which health economics revolves today. Given their complementary strengths, India and the US have an unencumbered opportunity to partner in building a sustainable and affordable global healthcare paradigm. This summit is an ideal platform for catalyzing collaborative innovation that can accelerate the delivery of affordable drugs to patients the world over said Kiran Mazumdar-Shaw, CMD, Biocon and USAIC Advisory Board member. Some of the most distinguished people in Biopharma will be discussing the role of latest technologies like CRISPR, Immune Checkpoint Inhibitor Therapy, Stem Cell Therapy etc., in changing the treatment paradigm of chronic diseases like cancer, neurodegenerative and some other rare diseases.”

“We believe India has a strong potential to become a hub for bio-pharma innovation and play a leading role in collaborative research for the same. There is a need for enhanced partnerships between Indian innovators, Government and academia as well as their American counterparts in order to realize India’s true potential as a bio-pharma hub.

"Now is the time for India to emerge as an innovator nation in the bio-pharmaceutical domain. Cultivating talent, setting goals, and collaborating across companies, the academia — industry interface, and national and research collaborations in India to improve access, advance new drug regimens and ensure responsible and appropriate use. Janssen will continue to strengthen its future leadership in innovation through an exciting late-stage pipeline and medicines under submission for approval in neuroscience, immunology, oncology, diabetes and infectious disease. We are committed to bringing these medicines to India to meet growing patient needs” said Dr Amrit Ray, Chief Medical Officer, Janssen Pharmaceutical Companies of Johnson & Johnson.

For Summit information and registration, please visit www.usaindiachamber.org

Email: info@usaindiachamber.org

USAIC - 10TH ANNUAL BIOPHARMA & HEALTHCARE SUMMIT